JoAnn H

[CG Oncology, Inc. @cgoncology]

Today, in honor of World Cancer Day, we want to raise awareness around the 5 early warning signs of bladder cancer. Thanks to #BCAN for sharing this information and urging people with these changes to see a urologist promptly for proper evaluation. Learn more here: https://t.co/f96M5iKmaR

#WorldCancerDay #BladderCancer #EarlyDetection

[CG Oncology, Inc. @cgoncology]

#BladderCancerAwarenessMonth #DidYouKnow? #FactFriday

[CG Oncology, Inc. @cgoncology]

New data shared at @UroOnc #SUO2024 highlights the potential of cretostimogene grenadenorepvec for BCG-unresponsive NMIBC if approved by the FDA.

Learn more: https://t.co/HmnTt4kSNJ

#SUO #BladderCancer #Urology

[CG Oncology, Inc. @cgoncology]

There were ~83,000 new cases of #bladdercancer in the U.S. in 2024.

Our investigational drug, cretostimogene grenadenorepvec, is designed to treat patients with BCG-unresponsive #NMIBC – which represents 75% of all new bladder cancer cases.

Learn more: https://t.co/H30Zzd2uIR

[JoAnn H @JMH1of6]

@WillTBerg @JustinLoloi Congratulations Justin Loloi. They are lucky to have you.

[CG Oncology, Inc. @cgoncology]

CG Oncology is proud to participate in the European Society of Medical Oncology Congress #ESMO24 this week in Barcelona to learn about the latest advances in oncology research and to engage with members of the global oncology community.

[CG Oncology, Inc. @cgoncology]

This month, CG Oncology joins the entire urology community in honoring September as Urological Cancer Awareness Month. To learn more visit the Urology Foundation at https://t.co/zmL8U8QoUh

[CG Oncology, Inc. @cgoncology]

🏙 Heading to #ASCO24? Our #patientcentric approach addresses all stages of #bladdercancer w/innovative #immunotherapies. Hear the final results of our CORE-001 Phase 2 trial, showcasing our commitment to improving patient outcomes & transforming care.

🔗 https://t.co/2BgAO9IhYF

[JoAnn H @JMH1of6]

@MontefioreNYC @JustinLoloi @EinsteinMed Congratulations Justin. So well deserved

[CG Oncology, Inc. @cgoncology]

📄Phase 2 CORE-001 Final Results: Cretostimogene in combination w/pembrolizumab for BCG-unresponsive HR-#NMIBC showed a 54% (19/35) complete response (CR) rate at 24 months. Poster will be presented at #ASCO24 @UrogerliMD @GarySteinbergMD @TBivala1 https://t.co/2BgAO9IPOd

[CG Oncology, Inc. @cgoncology]

👏 Thank you @BladderCancerUS and everyone who joined us for the 2024 Walk to End Bladder Cancer! It was a privilege to come together and take steps towards a cure. Let's keep raising awareness by supporting BCAN's mission here: https://t.co/ePuZ9QGxfn

[CG Oncology, Inc. @cgoncology]

👏 #AUA24 was incredible! We had a wonderful time connecting with colleagues and presenting our latest investigational data on cretostimogene alongside @MarkTysonMD and @SvatekRob, MD. Explore our advances in the fight against #bladdercancer at https://t.co/uQGws7yidR.

[JoAnn H @JMH1of6]

@JustinLoloi @MontefioreNYC @EinsteinMed @MontefioreUro Congratulations Justin! So exciting

[CG Oncology, Inc. @cgoncology]

It was a full house at the #AUA2024 "Clinical Trials in Progress, Bladder Cancer" session, featuring presentations by @SvatekRob on the PIVOT-006 study & @MarkTysonMD on the BOND-003- Cohort P. Learn more and discover our latest advances in #bladdercancer at booth #100! 🤝

[CG Oncology, Inc. @cgoncology]

Attending #AUA24 this week? Stop by booth #100 for exciting opportunities to explore our advances in #bladdercancer research & experience the MoA of cretostimogene through virtual reality. Hear from @CGOncology's Dr. Vijay Kasturi and meet our experts!

🤝 https://t.co/cOADzltuj9

[CG Oncology, Inc. @cgoncology]

We're incredibly inspired by all our @CGOncology BCAN Walk Teams who are committed to improving #patientcare through research. Join us again next month in one of the participating cities or in a virtual walk to #endbladdercancer 👉 https://t.co/ePuZ9QGxfn

[CG Oncology, Inc. @cgoncology]

With 80,000+ new #bladdercancer cases yearly, @cgoncology is committed to addressing the unmet needs of these #patients. Join us in the BCAN 2024 Walk to End Bladder Cancer, a united effort filled with hope to advance research.

👉 Find a walk near you: https://t.co/ePuZ9QGxfn

[CG Oncology, Inc. @cgoncology]

Sharing our announcement: $CGON

https://t.co/BtdTZtkh4m

[JoAnn H @JMH1of6]

@MontefioreUro @anorth21 Congratulations Amanda!

[CG Oncology, Inc. @cgoncology]

Our Phase 3 BOND-003 data presented at #SUO2023 shows a 75.7% response w/cretostimogene grenadenorepvec in #BCG-unresponsive #NMIBC patients. Thanks, @UrologyTimes & @UroToday, for sharing this "promising new #monotherapy."

👉 https://t.co/BLByTAziXN + https://t.co/zfZZCSmauC